Difference between revisions of "Volunteer Assignments and Opportunities"

From Compendium of Cancer Genome Aberrations
Jump to navigation Jump to search
VisualWikitext
[unchecked revision][unchecked revision]
Line 560: Line 560:
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Greg Corboy (GC)
+
|Diffuse Large B-cell Lymphoma, Not Otherwise Specified||Disease|| ||Greg Corboy (GC)
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||GC
+
|T-cell/Histiocyte-Rich Large B-cell Lymphoma||Disease|| ||GC
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Primary Diffuse Large B-cell Lymphoma of the CNS||Disease|| ||GC
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type||Disease|| ||GC
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|EBV-Positive Diffuse Large B-cell Lymphoma, Not Otherwise  Specified (NOS)||Disease|| ||GC
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|EBV-Positive Mucocutaneous Ulcer||Disease|| ||GC
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Diffuse Large B-cell Lymphoma Associated with Chronic  Inflammation||Disease|| ||GC
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|    Fibrin-Associated  Diffuse Large B-cell Lymphoma||Disease|| ||GC
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Lymphomatoid Granulomatosis||Disease|| ||GC
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Primary Mediastinal (Thymic) Large B-cell Lymphoma||Disease|| ||GC
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Intravascular Large B-cell Lymphoma||Disease|| ||GC
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|ALK-Positive Large B-cell Lymphoma||Disease|| ||GC
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Plasmablastic Lymphoma||Disease|| ||GC
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Primary Effusion Lymphoma||Disease|| ||GC
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|'''''HHV8-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''|| ||GC
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|   Multicentric Castleman  Disease||Disease|| ||GC
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|   HHV8-Positive Diffuse  Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease|| ||GC
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|   HHV8-Positive  Germinotropic Lymphoproliferative Disorder||Disease|| ||GC
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Burkitt Lymphoma||Disease|| ||GC
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Burkitt-Like Lymphoma with 11q Aberration||Disease|| ||GC
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|'''''High-Grade B-cell Lymphoma'''''||'''''Overview'''''|| ||GC
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|    High-Grade B-cell  Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements||Disease|| ||GC
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|    High-Grade B-cell  Lymphoma, Not Otherwise Specified (NOS)||Disease|| ||GC
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|B-cell Lymphoma, Unclassifiable, with Features Intermediate  Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma||Disease|| ||GC
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
| || || ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||Associate Editor??
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||
 
|
 
|
 
|
 
|
 
|}
 
|}

Revision as of 17:56, 21 May 2020

Disease Page Type Author Associate Editor Author Content (Pending or Complete) Editor Reviewed (Date)
Myeloproliferative Neoplasms (MPN) Overview Fabiola Quintero-Rivera (FQR)
    Chronic Myeloid Leukemia (CML), BCR-ABL1-Positive Disease FQR
    Chronic Neutrophilic Leukemia (CNL) Disease FQR
    Polycythaemia Vera (PV) Disease FQR
    Primary Myelofibrosis (PMF) Disease FQR
    Essential Thrombocythaemia (ET) Disease FQR
    Chronic Eosinophilic Leukemia, Not Otherwise Specified Disease FQR
    Myeloproliferative Neoplasm (MPN), Unclassifiable Disease FQR
Mastocytosis Overview FQR
    Cutaneous Mastocytosis Disease FQR
    Systemic Mastocytosis Disease FQR
    Mast Cell Sarcoma Disease FQR
Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2 Overview FQR
    Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement Disease FQR
    Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement Disease FQR
    Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement Disease FQR
    Myeloid/Lymphoid Neoplasms with PCM1-JAK2 Disease FQR
Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) Overview FQR
    Chronic Myelomonocytic Leukemia (CMML) Disease FQR
    Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative Disease FQR
    Juvenile Myelomonocytic Leukemia (JMML) Disease FQR
    Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) Disease FQR
    Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable Disease FQR
Myelodysplastic Syndromes (MDS) Overview FQR
    Myelodysplastic Syndrome (MDS) with Single Lineage Dysplasia Disease FQR
    Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS) Disease FQR
    Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia Disease FQR
    Myelodysplastic syndrome with multilineage dysplasiaMyelodysplastic Syndrome (MDS) with Multilineage Dysplasia Disease FQR
    Myelodysplastic Syndrome (MDS) with Excess Blasts Disease FQR
    Myelodysplastic Syndrome (MDS) with Isolated del(5q) Disease FQR
    Myelodysplastic Syndrome (MDS), Unclassifiable Disease FQR
    Refractory Cytopenia of Childhood Disease FQR
Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms Overview Jennelle Hodge (JH)
Myeloid Neoplasms with Germline Predisposition Overview JH
    Acute Myeloid Leukaemia with Germline CEBPA Mutation Disease JH
    Myeloid Neoplasms with Germline DDX41 Mutation Disease JH
    Myeloid Neoplasms with Germline RUNX1 Mutation Disease JH
    Myeloid Neoplasms with Germline ANKRD26 Mutation Disease JH
    Myeloid Neoplasms with Germline ETV6 Mutation Disease JH
    Myeloid Neoplasms with Germline GATA2 Mutation Disease JH
Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities Overview JH
    Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1 Disease JH
    Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 Disease JH
    Acute Promyelocytic Leukemia (APL) with PML-RARA Disease JH
    Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3 Disease JH
    Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214 Disease JH
    Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM Disease JH
    Acute Myeloid Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1 Disease JH
    Acute Myeloid Leukemia (AML) with BCR-ABL1 Disease JH
    Acute Myeloid Leukemia (AML) with Mutated NPM1 Disease JH
    Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA Disease JH
    Acute Myeloid Leukemia (AML) with Mutated RUNX1 Disease JH
Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes Disease JH
Therapy-Related Myeloid Neoplasms Disease JH
Acute Myeloid Leukemia (AML), Not Otherwise Specified Overview JH
    Acute Myeloid Leukemia (AML) with Minimal Differentiation Disease JH
   Acute Myeloid Leukemia (AML) without Maturation Disease JH
    Acute Myeloid Leukemia (AML) with Maturation Disease JH
    Acute Myelomonocytic Leukemia Disease JH
    Acute Monoblastic and Monocytic Leukemia Disease JH
    Pure Erythroid Leukemia Disease JH
    Acute Megakaryoblastic Leukemia (AMKL) Disease JH
    Acute Basophilic Leukemia Disease JH
    Acute Panmyelosis with Myelofibrosis Disease JH
Myeloid Sarcoma Disease JH
Myeloid Proliferations Associated with Down Syndrome Overview JH
    Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome Disease JH
    Myeloid Leukemia Associated with Down Syndrome Disease JH
Blastic Plasmacytoid Dendritic Cell Neoplasm Disease JH
Acute Leukemias of Ambiguous Lineage Overview JH
    Acute Undifferentiated Leukemia Disease JH
    Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 Disease JH
    Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged Disease JH
    Mixed Phenotype Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified Disease JH
    Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified Disease JH
    ??Mixed-Phenotype Acute Leukaemia, Not Otherwise Specified (NOS), Rare Types Disease JH
    ??Acute Leukaemias of Ambiguous Lineage, Not Otherwise Specified (NOS) Disease JH
Precursor Lymphoid Neoplasms Overview Yassmine Akkari (YA)
B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities Overview YA
    B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1     Disease YA
    B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged Disease YA
    B-Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1 Disease YA
    B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy Disease YA
    B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy Disease YA
    B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3 Disease YA
    B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1 Disease YA
    B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like Disease YA
    B-Lymphoblastic Leukemia/Lymphoma with iAMP21 Disease YA
    B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified Disease YA
T-Lymphoblastic Leukemia/Lymphoma Overview YA
Early T-Cell Precursor Lymphoblastic Leukemia Disease YA
NK-Lymphoblastic Leukemia/Lymphoma Disease YA
Mature B-Cell Neoplasms Overview Snehal Patel (SP)
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Disease SP
       Monoclonal B-cell Lymphocytosis Disease SP
B-cell Prolymphocytic Leukemia Disease SP
Splenic Marginal Zone Lymphoma Disease SP
Hairy Cell Leukemia Disease SP
Splenic B-cell Lymphoma/Leukemia, Unclassifiable Overview SP
    Splenic Diffuse Red Pulp Small B-cell Lymphoma Disease SP
    Hairy Cell Leukemia Variant Disease SP
Lymphoplasmacytic Lymphoma Disease SP
   Waldenstrom Macroglobulinemia Disease SP
IgM Monoclonal Gammopathy of Undetermined Significance Disease SP
Heavy Chain Diseases Overview SP
    Mu Heavy Chain Disease Disease SP
   Gamma Heavy Chain Disease Disease SP
    Alpha Heavy Chain Disease Disease SP
Plasma Cell Neoplasms Overview SP
   Non-IgM Monoclonal Gammopathy of Undetermined Significance Disease SP
    Plasma Cell Myeloma Disease SP
    Plasma Cell Myeloma Variants Disease SP
    Plasmacytoma Disease SP
    Monoclonal Immunoglobulin Deposition Diseases Overview SP
           Primary Amyloidosis Disease SP
           Light Chain and Heavy Chain Deposition Disease Disease SP
Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome Overview SP
         POEMS Syndrome Disease SP
         TEMPI Syndrome Disease SP
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) Disease SP
Nodal Marginal Zone Lymphoma Disease SP
    Paediatric Nodal Marginal Zone Lymphoma Disease SP
Follicular Lymphoma Disease SP
    Testicular Follicular Lymphoma Disease SP
    In Situ Follicular Neoplasia Disease SP
    Duodenal-Type Follicular Lymphoma Disease SP
Paediatric-Type Follicular Lymphoma Disease SP
Large B-cell Lymphoma with IRF4 Rearrangement Disease SP
Primary Cutaneous Follicle Centre Lymphoma Disease SP
Mantle Cell Lymphoma Disease SP
    Leukemic Non-Nodal Mantle Cell Lymphoma Disease SP
    In Situ Mantle Cell Neoplasia Disease SP
Diffuse Large B-cell Lymphoma, Not Otherwise Specified Disease Greg Corboy (GC)
T-cell/Histiocyte-Rich Large B-cell Lymphoma Disease GC
Primary Diffuse Large B-cell Lymphoma of the CNS Disease GC
Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type Disease GC
EBV-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS) Disease GC
EBV-Positive Mucocutaneous Ulcer Disease GC
Diffuse Large B-cell Lymphoma Associated with Chronic Inflammation Disease GC
    Fibrin-Associated Diffuse Large B-cell Lymphoma Disease GC
Lymphomatoid Granulomatosis Disease GC
Primary Mediastinal (Thymic) Large B-cell Lymphoma Disease GC
Intravascular Large B-cell Lymphoma Disease GC
ALK-Positive Large B-cell Lymphoma Disease GC
Plasmablastic Lymphoma Disease GC
Primary Effusion Lymphoma Disease GC
HHV8-Associated Lymphoproliferative Disorders Overview GC
   Multicentric Castleman Disease Disease GC
   HHV8-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS) Disease GC
   HHV8-Positive Germinotropic Lymphoproliferative Disorder Disease GC
Burkitt Lymphoma Disease GC
Burkitt-Like Lymphoma with 11q Aberration Disease GC
High-Grade B-cell Lymphoma Overview GC
    High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements Disease GC
    High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS) Disease GC
B-cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma Disease GC
Example Example Associate Editor??
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Example Example
Retrieved from "https://ccga.io/index.php?title=Volunteer_Assignments_and_Opportunities&oldid=7931"